The Smart Pills Market was estimated to be USD 3.52 billion in 2020 and is expected to register a CAGR of nearly 14.5% to reach USD 5.86 billion by the year 2026 during the forecast period of 2021-2026.
The COVID-19 pandemic has caused unintended consequences of severe delays in the diagnosis and treatment of various diseases. As per The Commonwealth Fund, it was estimated that there was a nearly 60% initial decrease in overall outpatient visits by the month of May 2020 due to COVID-19. This was expected to have negatively affected demand for smart pills as they are usually provided to patients in hospital settings. The outbreak of COVID-19 is likely to show an impact on the market growth because hospital and healthcare services were significantly reduced due to social distancing measures taken by governments across the globe. Moreover, the COVID-19 pandemic not only affected the global economy but also showed a huge impact on the functioning of general hospital care for non-COVID-19 patients in hospitals across the globe.
A smart pill may be a medical device with a small embedded electronic product in it, like sensors, cameras or trackers. The increased need for minimally invasive devices that are convenient and provide accurate therapeutic treatment strategies has led to an increased interest in research on smart pills. Products include Insulet Omnipod, the Medtronic MiniMed and Animas OneTouch Ping. These systems combine features of an insulin pump, a drug reservoir, a blood sugar monitor, and handheld management devices.
Controlled by electronics, a smart drug delivery pill is has great flexibility and precise control in dosage, delivery location, and release rate. Simultaneously, the pills can be used to monitor the local gastro-intestinal (GI) environment, report measurements in real-time, and be controlled by an operator to perform an action on demand. Smart pills eliminate the need for invasive procedures as wireless communication allows the transmission of real-time information. Advances in battery technology (providing longer life) and on-board memory make them useful for long-term sensing from within the body. In the future, smart pills are likely to become an important part of remote patient monitoring and telemedicine. This sort of multi-dimensional performance is impossible with conventional oral drug forms. Smart pills have revolutionized the diagnosis of gastrointestinal disorders is likely to replace the need for conventional diagnostic techniques like endoscopy. Traditionally, an endoscopy probe is inserted into a patient's esophagus, and subsequently the upper and lower alimentary canal , for diagnostic purposes
Additional uses can be in the delivery of insulin. The delivery of insulin is tailored to the patient's current blood sugar level and should be delivered on demand by the patient, for instance at mealtime is that the emerging area of wearable bolus injection devices. Increase in research and development in this field is expected to have apostive impact on the smart pill market. In 2019, Massachusetts Institute of Technology (MIT) researchers also developed a smart pill SOMA, or self-orienting millimeter-scale applicator, which contains the same type of insulin used in the conventional kits. The pill consists of a capsule and a tiny needle, which is made from freeze-dried insulin. Once the pill is ingested, its sugar-based coating dissolves in water and releases needle and injects it into the stomach.
Key Market Trends
Capsule Endoscopy Application is Expected to Hold Largest Share of Global Smart Pills Market over the Forecast Period
Capsule endoscopy is the most commonly used application area for smart pills. Capsule endoscopy is an important application area, as smart pills are used to treat related disease in the GI tract, which includes Crohn's disease, obscure GI bleeding, celiac disease, and small bowel tumors. These pills target the small bowel, which is seen as a golden standard if GI bleeding is suspected.
Conventional scopes that are used for colonoscopy are uncomfortable for the patients. This has given rise to the demand for smart pills. As these pills have revolutionized the diagnosis of gastrointestinal disorders, they are expected to replace conventional endoscopy, for certain indications. In 2019, the National Institutes of Health in the United States had stated that advancements in capsule endoscopy are being done rapidly, and in the near future, doctors will be able to control the movement of the device with an interface application inside the body. Through this technique, they can easily inspect or diagnose any part inside the body. Thus, with the continuous advancements that are being done in the area of endoscopy, and with the rising need for proper diagnosis of gastrointestinal disorders, it is expected that the market studied will have rapid growth over the forecast period.
Many organizations are also providing grants so that research and development could be conducted in the field of smart pill development. For example, in December 2020, University College London provided GBP 150k to a gut health startup company called Enteromics which was developing smart pills. The company is developing a range of smart pills to monitor and detect chronic diseases, starting with Inflammatory Bowel Disease (IBD).
North America Region Holds the Largest Market Share of Smart Pills Market
North America currently dominates the Smart Pills market, owing to factors such as an increase in the prevalence of colorectal cancer, technological advancements in the healthcare sector, and regulatory approval of new products. All these factors are expected to provide growth opportunities for the players operating in this region.
As per the Journal of the Canadian Association of Gastroenterology in 2018, Canada was one of the countries with the highest prevalence and incidence of IBD (Inflammatory bowel disease) in the world. The number of Canadians living with IBD was approximately 270,000 and is predicted to rise to 403,000 by 2030. IBD affects all age groups, with adolescents and young adults at the highest risk of diagnosis. Endoscopy is used extensively in the management, diagnosis, and treatment of inflammatory bowel disease. As smart pills are more convenient to use as compared to traditional endoscopy, their use is expected to increase.
Research and development activities in the region are also expected to fuel market growth. In 2018, researchers from the Massachusetts Institute of Technology (MIT) created an ingestible capsule made with 3D printing technology, which communicates via Bluetooth. The capsule, once swallowed, can stay for a month inside the body. During that time, the capsule would collect information about the patient's body and will transmit the data to a smartphone for analysis. Such product innovations are likely to affect market growth in a positive manner.
The market is moderately competitive. Competition is set to intensify, as several key players are focusing on the expansion of their smart pills portfolio, through acquisition and collaboration with companies. The smart pills market is expected to open up several opportunities for new players, as well as for currently established market leaders. The major companies operating in this market include CapsoVision Inc., Medtronic PLC, Otsuka Pharmaceutical Co. Ltd, etectRx Inc, and HQ Inc.
The companies in this market are involved in various strategies such as new product launches, investment in research and development activities to sustain in the highly competitive environment. For example, in December 2019, etectRx, a Florida-based company received approval from the United States Food and Drug Administration for its sensor technology which is used in smart pills.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Increasing Preference for Minimally-invasive Devices
- 4.2.2 Rising Burden of Gastrointestinal Disorders
- 4.2.3 Technological Advancements
- 4.3 Market Restraints
- 4.3.1 Increasing Cost with Technological Advancements
- 4.3.2 Potential Health Risks
- 4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Application Area
- 5.1.1 Capsule Endoscopy
- 188.8.131.52 Small Bowel Video Capsule Endoscopy
- 184.108.40.206 Colon Capsule Endoscopy
- 5.1.2 Patient Monitoring
- 5.1.3 Drug Delivery
- 5.2 By Disease Indication
- 5.2.1 Occult GI Bleeding
- 5.2.2 Crohn's Disease
- 5.2.3 Small Bowel Tumors
- 5.2.4 Celiac Disease
- 5.2.5 Inherited Polyposis Syndromes
- 5.2.6 Neurological Disorders
- 5.2.7 Other Disease Indications
- 5.3 Geography
- 5.3.1 North America
- 220.127.116.11 United States (By Application Area, and By Disease Indication)
- 18.104.22.168 Canada (By Application Area, and By Disease Indication)
- 22.214.171.124 Mexico (By Application Area, and By Disease Indication)
- 5.3.2 Europe
- 126.96.36.199 Germany (By Application Area, and By Disease Indication)
- 188.8.131.52 United Kingdom (By Application Area, and By Disease Indication)
- 184.108.40.206 France (By Application Area, and By Disease Indication)
- 220.127.116.11 Italy (By Application Area, and By Disease Indication)
- 18.104.22.168 Spain (By Application Area, and By Disease Indication)
- 22.214.171.124 Rest of Europe (By Application Area, and By Disease Indication)
- 5.3.3 Asia-Pacific
- 126.96.36.199 China (By Application Area, and By Disease Indication)
- 188.8.131.52 Japan (By Application Area, and By Disease Indication)
- 184.108.40.206 India (By Application Area, and By Disease Indication)
- 220.127.116.11 Australia (By Application Area, and By Disease Indication)
- 18.104.22.168 South Korea (By Application Area, and By Disease Indication)
- 22.214.171.124 Rest of Asia-Pacific (By Application Area, and By Disease Indication)
- 5.3.4 Middle East and Africa
- 126.96.36.199 GCC (By Application Area, and By Disease Indication)
- 188.8.131.52 South Africa (By Application Area, and By Disease Indication)
- 184.108.40.206 Rest of Middle East and Africa (By Application Area, and By Disease Indication)
- 5.3.5 South America
- 220.127.116.11 Brazil (By Application Area, and By Disease Indication)
- 18.104.22.168 Argentina (By Application Area, and By Disease Indication)
- 22.214.171.124 Rest of South America (By Application Area, and By Disease Indication)
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 CapsoVision Inc.
- 6.1.2 Medtronic PLC
- 6.1.3 Novartis AG
- 6.1.4 Olympus Medical Technology
- 6.1.5 Pentax Medical (Hoya)
- 6.1.6 Koninklijke Philips NV (Medimetrics)
- 6.1.7 CapsoVision Inc.
- 6.1.8 Check-Cap
- 6.1.9 Otsuka Pharmaceutical Co. Ltd
- 6.1.10 Intromedic
- 6.1.11 etectRx Inc
- 6.1.12 Pixie Scientific
- 6.1.13 HQ Inc.
- 6.1.14 Jinshan Science and Technology
7 MARKET OPPORTUNITIES AND FUTURE TRENDS